Lipocine (LPCN) Q3 2025 earnings summary

Executive summary

• Focus on oral drug delivery for CNS disorders, liver diseases, hormone supplementation, postpartum depression, epilepsy, and obesity management, with a pipeline including LPCN 1154, LPCN 2401, LPCN 2101, and LPCN 2203.

• Commercialization of TLANDO (oral testosterone therapy) through licensing agreements in the US, Canada, South Korea, GCC, and Brazil, with milestone and royalty payments.

• Ongoing Phase 3 trial for LPCN 1154 in postpartum depression, with top-line data expected in Q2 2026 and NDA submission planned for 2026.

• Exploring proof-of-concept studies for epilepsy (LPCN 2101) and obesity (LPCN 2401), with partnership discussions ongoing.

Financial highlights

• Total revenue for Q3 2025 was $115,000, all from royalty revenue; no license revenue recognized in the quarter.

• Net loss for Q3 2025 was $3.2 million ($0.59 per share), compared to $2.2 million ($0.44 per share) in Q3 2024.

• For the nine months ended September 30, 2025, revenue was $831,000 (license: $500,000; royalty: $331,000), down from $7.7 million in the prior year period.

• Research and development expenses increased to $2.7 million in Q3 2025, mainly due to the LPCN 1154 Phase 3 trial.

• Cash, cash equivalents, and marketable investment securities totaled $15.1 million as of September 30, 2025.

Outlook and guidance

• Existing capital resources are expected to fund operations through at least November 6, 2026, including ongoing clinical studies.

• Top-line data from the LPCN 1154 Phase 3 trial expected in Q2 2026; NDA submission planned for 2026.

• Additional capital will be needed for further development, regulatory compliance, and potential new clinical trials.

• The company is actively seeking partnerships and licensing opportunities for pipeline assets.